English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduA rapid genetic testing model for patients with advanced prostate cancer can more quickly identify those with “actionable” gene variants eligible for newer targeted therapies, reports a clinical trial in the May issue of The Journal of Urology®, an Official Journal of the American Urological Association (AUA). The journal is published in the Lippincott portfolio by Wolters Kluwer.
Tag: Prostatic neoplasms
Falling PSA levels predict longer survival in prostate cancer patients at high risk of metastases
Declines in prostate-specific antigen (PSA) level after treatment with the next-generation androgen receptor inhibitor drug enzalutamide predict improved survival rates in men with non-metastatic castration-resistant prostate cancer (nmCRPC), reports The Journal of Urology®, an Official Journal of the American Urological Association (AUA). The journal is published in the Lippincott portfolio by Wolters Kluwer.
New therapies have raised Medicare treatment costs for metastatic prostate cancer
Medicare costs for treatment of metastatic prostate cancer have risen sharply within the last 15 years – reflecting increased use of new medications under Medicare Part D, reports a study in Urology Practice®, an Official Journal of the American Urological Association (AUA). The journal is published in the Lippincott portfolio by Wolters Kluwer.
Treatment without hormone blockers improves outcomes in solitary prostate cancer metastases
For patients with solitary metastases from prostate cancer, an approach called metastasis-directed therapy (MDT) – focused treatment using surgery or radiation therapy, without androgen deprivation therapy (ADT) – can slow the time to cancer progression, reports a study in The Journal of Urology®, an Official Journal of the American Urological Association (AUA). The journal is published in the Lippincott portfolio by Wolters Kluwer.
3D virtual reality models improve ‘trifecta’ outcomes of prostate cancer surgery
Providing surgeons with 3D virtual reality (VR) models for surgical planning can help to achieve the critical “trifecta” outcomes of prostate cancer surgery: controlling the cancer while maintaining patient’s sexual function and urinary continence, suggests a study in The Journal of Urology®, an Official Journal of the American Urological Association (AUA). The journal is published in the Lippincott portfolio by Wolters Kluwer.
‘Financial toxicity’ of prostate cancer treatment: Radiation therapy has the greatest impact on patient finances
For men with early-stage prostate cancer, choices about initial treatment carry varying risks of “financial toxicity,” reports a study in The Journal of Urology®, Official Journal of the American Urological Association (AUA). The journal is published in the Lippincott portfolio by Wolters Kluwer.
For African American men with prostate cancer, decision regret linked to medical mistrust
Medical mistrust is one reason why African American patients are more likely to have regrets about their choice of treatment for prostate cancer, suggests a study in The Journal of Urology®, Official Journal of the American Urological Association (AUA). The journal is published in the Lippincott portfolio by Wolters Kluwer.
‘Vanished’ or ‘hidden’ prostate cancer? Men with negative biopsies during active surveillance have good outcomes
Can early-stage prostate cancer “vanish” during follow-up? More likely the cancer is just “hidden”—either way, negative biopsies during active surveillance for prostate cancer are associated with excellent long-term outcomes, reports a study in The Journal of Urology®, an Official Journal of the American Urological Association (AUA). The journal is published in the Lippincott portfolio by Wolters Kluwer.
High-Intensity Focused Ultrasound for Prostate Cancer: First US Study Shows Promising Outcomes
High-intensity focused ultrasound (HIFU) – a technology used to treat localized prostate cancer – has shown adequate control of prostate cancer while avoiding major side effects of surgery or radiation therapy, according to a new study in The Journal of Urology®, Official Journal of the American Urological Association (AUA). The journal is published in the Lippincott portfolio by Wolters Kluwer.